Their terms take effect upon final certification of the results of the stockholder vote by IVS Associates.
According to a release, the Company also announced that the preliminary tabulation by IVS Associates confirms stockholders voted to institute majority voting in uncontested elections, ratify the Company's auditor, and reject proposals to change the Company's jurisdiction of incorporation to North Dakota and set the size of the Board at 13.
Bruce R. Ross, Biogen Idec's Chairman, said, "We welcome Alexander Denner and Richard Mulligan to the Board and look forward to working with them to build on Biogen Idec's strong track record of delivering value."
Biogen Idec is a global company engaged in the discovery, development, manufacturing, and commercialization of therapies.
((Comments on this story may be sent to health@closeupmedia.com))

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index